NEWS

  • Immuno-Oncology Essentials (IO Essentials) Initiative Featured at ASCO-SITC and Other Scientific Conferences

    Richmond, CA. May 3, 2019—The AIM with Immunotherapy Foundation, in collaboration with Terranova Medica, LLC, is pleased to announce that the resources for the Immuno-Oncology Essentials (IO Essentials) Initiative have been featured at a range of scientific conferences, including a poster presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, February 28-March 2, 2019, in San Francisco.

    The poster, entitled Managing Immune-Related Adverse Events (irAEs): A New Educational Resource for Health Care Professionals (HCPs) and Patients, was developed by several of the IO Essentials faculty as well as key staff at AIM With Immunotherapy and Terranova Medica. The poster provided a review of key IO Essentials resources, including:

    • Care Step Pathways (CSPs): Step-by-step assessment, grading, and management guides for notable irAEs associated with immune checkpoint inhibitor (ICI) therapy
    • HCP Toolkits: Quick and easy guides to individual therapies, including key dosing/administration information, immune-related adverse event (irAE) management information, clinical pearls, Q/A, and resources
    • Patient Action Plans: Customizable, printable pages for HCPs to share with patients on drug administration, side effects, and resources
    • HCP and Patient Directed Videos: Short video segments on immunotherapy and irAE recognition and management

    For convenient searching, the IO Essentials content on AIMWithImmunotherapy.org is grouped by drug and by tumor type and is optimized for use on both PC/tablets and mobile devices. First author of the poster, Laura S. Wood, RN, MSN, OCN, noted that, “Immunotherapy is rapidly changing our practice in oncology. Having easy-to-access resources Is really critical to help us face these challenges.”  While there are many resources available on irAE management, the IO Essentials tools are practical, easily accessible resources for identification, grading, and management of irAEs.

    Also at the 2019 ASCO-SITC meeting, IO Essentials faculty member Marianne J. Davies DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, delivered an oral presentation, Tumor Board: Toxicity Management and Moderating Case Reports. Strategies to Support Multidisciplinary Management.  In this talk, Dr Davies highlighted the practical applicability of the HCP toolkits as clinical practice guidelines to use in the clinic setting as well as the value and easy access of the printable patient action plans to educate patients.

    The faculty/staff have presented materials on the IO Essentials Initiatives at various other scientific meetings since the AIMWithImmunotherapy.org site launched in October. Advanced practice provider faculty, including Brianna Hoffner, Laura Zitella, Marianne Davies, and Laura Wood, have presented as has Valerie Guild of AIM at Melanoma. The meetings at which they have spoken about IO Essentials include:

    • JADPRO Live; November 2, 2018; Hollywood, Florida
    • SITC 33rd Annual Meeting; November 7, 2018; Washington, DC
    • European Association of Dermato-Oncology Annual Meeting; November 8, 2018; Barcelona, Spain
    • Advances in Cancer Immunotherapy™; April 4, 2019; Toronto, Ontario
    • ONS Annual Meeting; April 11, 2019; Anaheim, California
    • SWOG Immune-Related Adverse Events Symposium; April 26, 2019; San Francisco, California

    An upcoming presentation is scheduled at the Melanoma Education Symposium, May 18, 2019, at the Mayo Clinic in Rochester, Minnesota. For more information, see https://ce.mayo.edu/hematology-and-oncology/content/melanoma-education-symposium-2019.

    All of these presentations reflect the commitment and energy behind the excellent IO Essentials faculty. According to Dr Lisa Tushla of Terranova Medica, “We are extremely excited by the efforts our faculty and staff have taken to get the word out about the IO Essentials Initiative. We look forward to keeping the momentum rolling as we continue enhancing the IO Essentials offerings, including plans to bring the content to an international audience and address multidisciplinary management through additional continuing education opportunities.”

     

    References:

    Laura S. Wood, Brianna Hoffner, Krista M. Rubin, Marianne Davies, Lisa A. Tushla, Valerie Guild, and Samantha R. Guild.  Managing immune-related adverse events (irAEs): A new educational resource for health care professionals (HCPs) and patients. J Clin Oncol 37, 2019 (suppl 8; abstr 75). Available at https://meetinglibrary.asco.org/record/170456/abstract

    Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP®. Tumor board: Toxicity management and moderating case reports. Strategies to support multidisciplinary management. Presented at ASCO-SITC 2019. Available at https://www.facebook.com/IOEssentials/videos/634373153670338/

     

    About AIM with Immunotherapy

    The AIM with Immunotherapy Foundation is a not-for-profit sister organization of the AIM at Melanoma Foundation. AIM at Melanoma is the largest international melanoma foundation globally engaged and locally invested in advancing the battle against melanoma through innovative research, legislative reform, education, and patient and caregiver support. In terms of innovation in melanoma research, AIM employs groundbreaking international research initiatives and unparalleled tools and resources in the battle for the cure. In terms of global engagement and advocacy, AIM makes a difference globally through education and advocacy e􀁷orts such as the International Melanoma Working Group (IMWG), an expert think tank involving a worldwide group of melanoma experts. Finally, in terms of education and support, AIM provides answers, information, and support for everyone touched by melanoma.

     

    About Terranova Medica:

    Terranova Medica, LLC, is a medical education company whose mission is to deliver high-quality educational initiatives to meet the needs of the healthcare professional and patient, with a special emphasis on interactive e-learning in infectious diseases and oncology. Terranova’s principal, Lisa Tushla, PhD, H(ASCP), is a trained bench scientist with extensive clinical/research experience in both solid tumors and hematologic malignancies. She also has over 15 years’ experience developing interdisciplinary educational initiatives in oncology and is the recipient of 2 Alliance for Continuing Education Awards for Outstanding Collaboration for melanoma and multiple myeloma curricula. Terranova has been collaborating with AIM on various programs since 2009, including seminal publication support for manuscripts published in Cancer, Journal of Surgical Oncology, and Melanoma Research.

     

    Media Contacts:

    For AIM With Immunotherapy: Valerie Guild, 415-305-0060, vguild@aimatmelanoma.org

    For Terranova Medica: Tom Davis, 877-276-4523, tdavis@terranovamedica.com